Low-Cost HIV Alliance To Restore GSK’s China Image?
This article was originally published in PharmAsia News
Executive Summary
Although it is still awaiting approval from the China FDA for its widely-sold and fast-growing HIV drug, GSK unit ViiV has linked a deal with a Chinese firm to manufacture low-priced Tivicay in the country. The arrangement could be a preemptive move as China is increasing pressure on the prices of costly new therapies for infectious diseases.